Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Rigel Pharmaceuticals Inc (RIGL)
A forensic read on Rigel Pharmaceuticals Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
3.5
Distress distance
Watch
Earnings quality
5
Forensic signals
2.1
P / E (ttm)
93.8%
ROE
$768M
Market cap
64.1%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Rigel Pharmaceuticals Inc earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 3.5, placing it in the Safe zone. 5 forensic signals were flagged in its latest SEC filings, led by cash conversion.
What the filings flag
0.28×
FY2023–FY2025
Cash conversion.Over FY2023–FY2025, operating cash flow was 0.28× cumulative net income. Reported profit is not turning into cash. The shortfall is profit tied up in working capital rather than collected — the accrual and receivables lines below show where.
+193.6%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +193.6% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The build is led by inventory up +92% against +5% in cost of sales and receivables up +24% against revenue +64%. The cash-flow cross-check agrees: reported earnings ran ahead of operating cash by 142% of net operating assets.
163d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 113 to 163 FY2024→FY2025 (against cost of goods sold; inventory +92% vs +5% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
+3.4%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +11% over the last 3 years to FY2025 (+3.4%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. Note: the share count shows a large one-time jump around FY2019, consistent with a reverse split or bankruptcy reorg rather than gradual buybacks, so the earlier shrinkage doesn't reflect real repurchase discipline. That's ~3.4% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~10%.
Key fundamentals
Latest Revenue$294.3M
Revenue Growth YoY+64.1%
Revenue CAGR (3yr)+34.8%
Net Margin124.7%
Return on Equity93.8%
Debt / Equity0.13x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Rigel Pharmaceuticals Inc's actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.
4% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 4% of revenue in FY2025 — about $0.67 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 3.4% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.